ClinicalTrials.gg
CompletedNCT02983227Updated Aug 3, 2020Results posted

A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350

A Phase 2 interventional study of GDC-0853 in Rheumatoid Arthritis, sponsored by Genentech, Inc.. Completed at 104 sites in 10 countries. Open to participants aged 18 Years to 76 Years. Per ClinicalTrials.gov, last updated 2020-08-03.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
496
Ages
18 Years to 76 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Hoffmann-La Roche.

Enrollment
28th of 141
496 · median 132
Started
2016
with 7 others
Phase 2
20 of 219
2 open now
Registered
213th of 219
by date

Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 28th largest by enrollment of the 141 interventional ones that give a count, is one of 8 that started in 2016, is one of 20 in phase 2, and was the 213th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 76 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, or all of them as a file.
02

Study summary

A study to evaluate the long-term safety and efficacy of GDC-0853 in participants with moderate to severe active Rheumatoid Arthritis (RA) who have completed 12 weeks of study treatment in Study GA29350. Eligible participants from Study GA29350 who elect to participate will receive treatment with GDC-0853 twice daily (BID) in an open-label fashion for 52 weeks, followed by a safety follow-up period of 8 weeks.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 76 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completion of treatment as specified in Study GA29350, including completion of the Day 84 study visit assessments
  • Acceptable safety and tolerability during Study GA29350 as determined by the investigator or Medical Monitor
  • Have not received any prohibited medications in Study GA29350
  • While taking methotrexate, must be willing to receive oral folic acid (at least 5 milligrams per week [mg/week])
  • If receiving oral (less than or equal to [\</=] 10 milligrams per day [mg/day] prednisone or equivalent) and/or non-steroidal anti-inflammatory drugs, doses have remained stable for the duration of Study GA29350

Exclusion criteria

Exclusion Criteria:

  • Met protocol defined treatment stopping criteria during Study GA29350
  • Treatment with any agent (i.e., other than study drug) or live/attenuated vaccine or any other prohibited medication during Study GA29350 or since the last administration of study drug in Study GA29350
  • In the opinion of the investigator, any new (since initially enrolling in the Phase II Study GA29350), significant, uncontrolled comorbidity that would increase the risk to the participant in Study GA30067
  • Pregnant or lactating, or intending to become pregnant during the study
  • Participants who experienced a de novo or reactivated serious viral infection such as virus (HBV), virus (HCV), or (HIV) during the Phase II Study GA29350
  • Any major episode of infection requiring hospitalization or treatment with intravenous antibiotics during the Phase II Study GA29350
  • Participants who developed a during the Phase II Study GA29350
  • 12-lead (ECG) on Day 84 in Study GA29350 that demonstrates abnormalities that may affect participant safety or interpretation of study results
  • Current treatment with medications that are well known to prolong the
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
496 participants (actual)

Study arms

  • Experimental
    GDC-0853 (200mg BID) Cohort 1

    Participants received GDC-0853 orally twice daily (BID) for 52 weeks, after completing 12 weeks in Cohort 1 of Study GA29350. Cohort 1 participants in GA29350 were enrolled with moderate to severe active Rheumatoid Arthritis (RA) and an inadequate response to previous methotrexate (MTX) therapy and then randomized to 12 weeks of GDC-0853 (50 mg daily, 150 mg daily, or 200 mg BID), adalimumab, or placebo.

    Drug: GDC-0853

  • Experimental
    GDC-0853 (200mg BID) Cohort 2

    Participants received GDC-0853 orally twice daily (BID) for 52 weeks, after completing 12 weeks in Cohort 2 of Study GA29350. Cohort 2 participants in GA29350 were enrolled with moderate to severe active Rheumatoid Arthritis (RA) and an inadequate response to one or two tumor necrosis factor (TNF) inhibitors and methotrexate (MTX) therapy, and then randomized to 12 weeks of GDC-0853 (200 mg BID) or placebo.

    Drug: GDC-0853

Interventions

  • GDC-0853 was administered orally at a dose of 200mg, as per the dosing schedules described above.

    Also known as: RO7010939

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs)

    An Adverse Event (AE) was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events.

    Time frame: Day 1 up until 8 weeks after the last dose of study drug (up to 1 year, 2 months)

  2. Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Week 52

    ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

    Time frame: Week 52

Secondary outcomes

  1. Percentage of Participants Achieving ACR50 Response up to Week 12

    ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

    Time frame: Weeks 4, 8 and 12

  2. Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response

    ACR20 response is defined as a ≥ 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\]

    Time frame: Weeks 4, 8, 12, 24, 36 and 52

  3. Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response

    ACR70 response is defined as a ≥ 70% improvement (reduction) compared with Baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

    Time frame: Weeks 4, 8, 12, 24, 36 and 52

  4. Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 CRP)

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36 and 52

  5. Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (4 Variables) (DAS28-4 CRP)

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36 and 52

  6. Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 ESR)

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36 and 52

  7. Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 ESR)

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36 and 52

  8. Percentage of Participants With Remission Based on Disease Activity Score Based on 28-Joints Count (DAS28)

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control.

    Time frame: Weeks 4, 8, 12, 24, 36 and 52

  9. Percentage of Participants With Low Disease Activity (LDA) Based on DAS28

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. LDAS is defined as DAS28 ≤ 3.2

    Time frame: Weeks 4, 8, 12, 24, 36 and 52

  10. Percentage of Participants With ACR/EULAR Remission

    Assessed according to the Boolean based definition (tender joint count =\<1, swollen joint count =\<1, C-reactive Protein (CRP) =\<1, and patient global assessment =\<1)

    Time frame: Weeks 4, 8, 12, 24, 36 and 52

  11. Change From Baseline in Simplified Disease Activity Index (SDAI)

    Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity

    Time frame: Weeks 4, 8, 12, 24, 36 and 52

  12. Change From Baseline in Clinical Disease Activity Index (CDAI)

    CDAI was derived as the sum of the following: tender joint count (TJC), swollen joint count (SJC), participant global assessment (PGA) of disease activity, and physician assessment of disease activity. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA and physician assessment of disease activity were scored 0-100 millimeters (mm) and rounded to the nearest centimeter (cm) on a visual analog scale (VAS), where higher scores indicate greater perceived disease activity. The total CDAI score range was 0-76, where higher scores indicate increased disease activity. Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest. Negative values indicate improvement/reduction in RA disease activity.

    Time frame: Weeks 4, 8, 12, 24, 36 and 52

  13. Change From Baseline in Tender/Painful Joint Count Based on 68 Joints

    Tender Joint Count: a total of 68 joints will be assessed for tenderness. Each joint is assessed for the presence/absence of tenderness. 68 joints are assessed for tenderness and joints are classified as tender/not tender giving a total possible tender joint count score of 0 to 68. A negative change from Baseline indicated improvement.

    Time frame: Weeks 4, 8, 12, 24, 36 and 52

  14. Change From Baseline in Swollen Joint Count Based on 66 Joints

    Swollen Joint Count: a total of 66 joints will be assessed for swelling. Each joint is assessed for the presence/absence of swelling. 66 joints were assessed for swelling and joints are classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66. A negative change from Baseline indicated improvement.

    Time frame: Weeks 4, 8, 12, 24, 36 and 52

  15. Change From Baseline in Patient's Assessment of Arthritis Pain, Using Visual Analog Scale (VAS) Score

    Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain

    Time frame: Weeks 4, 8, 12, 24, 36 and 52

  16. Change From Baseline in Patient's Global Assessment of Arthritis, Using VAS Score

    Participant-assessed arthritis pain was scored on a 100-mm VAS, where the distance from 0 mm represented the participant's self evaluation of arthritis pain (0 mm=none; 100 mm=very severe). Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest, where negative change indicated a decrease in participant-assessed arthritis pain.

    Time frame: Weeks 4, 8, 12, 24, 36 and 52

  17. Change From Baseline in Physician's Global Assessment of Arthritis, Using VAS Score

    Physician's assessment of participant's disease activity was scored on a 100-mm VAS, where the distance from 0 mm represented the physician's assessment of the participant's disease activity (0 mm=very good; 100 mm=very poor). Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest, where negative change from baseline indicated an improvement in physician-assessed disease activity.

    Time frame: Weeks 4, 8, 12, 24, 36 and 52

  18. Change From Baseline in C-Reactive Protein (CRP) Levels

    C-reactive protein is a biological marker of inflammation and is measured in milligrams per decilitre (mg/dL)

    Time frame: Weeks 4, 8, 12, 24, 36 and 52

  19. Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score

    The Stanford Health Assessment Questionnaire disability index is a patient-reported outcome used to assess difficulty in performing activities of daily living. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. To respond to each question, a four-level response with higher scores showing larger functional limitations, was chosen. Scoring is as follows with respect to performance of participant's everyday activities: 0 (equals)=without difficulties; 1= with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. The composite HAQ-DI score is the mean of the eight domain scores and the score ranges from 0 (no functional impairment) to 3 (maximum functional impairment). A negative change from baseline indicates improvement.

    Time frame: Weeks 4, 8, 12, 24, 36 and 52

  20. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Version 2.0 (V2) Scores for Physical and Mental Components

    The 36-Item Short Form Health Survey (SF-36v2) is a questionnaire used to assess functional health and well-being and consists of eight domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. The SF-36v2 is summarized into Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. The PCS and MCS scores range from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.

    Time frame: Weeks 12, 24 and 52

  21. Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score

    The FACIT-Fatigue Scale consists of 13 items designed to measure the degree of fatigue experienced by the patient in the previous 7 days. For each question, there are five possible responses: 0 (not at all), 1 (a little bit), 2 (somewhat), 3 (quite a bit), 4 (very much). A total fatigue score is calculated by summing all items, and possible total scores range from 0 (maximum fatigue) to 52 (no fatigue). A positive change from baseline indicates an improvement in the patient's fatigue (less fatigue).

    Time frame: Weeks 12, 24 and 52

  22. Area Under the Concentration Time Curve (AUC) of GDC-0853 at Steady State (AUC,ss)

    Population PK model estimated AUC of GDC-0853 at steady-state. AUC was measured in Nanograms (ng) per millilitre(mL)\*hour (hr).

    Time frame: Pre-dose (0 hour) on Weeks 0 (Day 1), 4, 12, 24, 36, and 52/early termination

  23. Minimum Plasma Concentration of GDC-0853 at Steady State (Ctrough,ss)

    Population PK model estimated minimal plasma concentration (Ctrough) of GDC-0853 at steady-state (ss).

    Time frame: Pre-dose (0 hour) on Weeks 0 (Day 1), 4, 12, 24, 36, and 52/early termination

  24. Plasma Decay Half-Life of GDC-0853 at Steady State (t1/2,ss)

    Population PK model estimated plasma decay half life of GDC-0853 at steady-state.

    Time frame: Pre-dose (0 hour) on Weeks 0 (Day 1), 4, 12, 24, 36, and 52/early termination

  25. Apparent Oral Clearance of GDC-0853 at Steady State (CL/F,ss)

    Population PK model estimated apparent oral clearance of GDC-0853 at steady-state.

    Time frame: Pre-dose (0 hour) on Weeks 0 (Day 1), 4, 12, 24, 36, and 52/early termination

07

Results

Posted Aug 3, 2020

Participant flow

The study was conducted at 138 centers in 19 countries.

Participant flow — Overall Study
MilestoneGDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
Started41086
Completed35172
Not completed5914
Withdrew: Adverse event213
Withdrew: Death30
Withdrew: Lack of efficacy81
Withdrew: Lost to follow-up30
Withdrew: Multiple reasons21
Withdrew: Physician decision31
Withdrew: Withdrawal by subject198

Outcome measures

PrimaryPercentage of Participants With Adverse Events (AEs)

An Adverse Event (AE) was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events.

Time frame:
Day 1 up until 8 weeks after the last dose of study drug (up to 1 year, 2 months)
Reported as:
Number · Percentage
Percentage of Participants With Adverse Events (AEs)
PercentageGDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
Percentage of Participants With Adverse Events (AEs)60.257.0
PrimaryPercentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Week 52

ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

Time frame:
Week 52
Reported as:
Number · Percentage
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Week 52
PercentageGDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Week 5257.1 (52.28 to 61.86)50.0 (39.43 to 60.57)
SecondaryPercentage of Participants Achieving ACR50 Response up to Week 12

ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

Time frame:
Weeks 4, 8 and 12
Reported as:
Number · Percentage
Percentage of Participants Achieving ACR50 Response up to Week 12
PercentageGDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
Week 437.1 (32.40 to 41.75)29.1 (19.47 to 38.67)
Week 842.4 (37.65 to 47.22)34.9 (24.81 to 44.96)
Week 1245.6 (40.79 to 50.43)39.5 (29.20 to 49.87)
SecondaryPercentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response

ACR20 response is defined as a ≥ 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\]

Time frame:
Weeks 4, 8, 12, 24, 36 and 52
Reported as:
Number · Percentage
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response
PercentageGDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
Week 469.0 (64.55 to 73.50)58.1 (47.71 to 68.57)
Week 872.9 (68.63 to 77.23)68.6 (58.80 to 78.41)
Week 1274.4 (70.17 to 78.62)73.3 (63.90 to 82.61)
Week 2475.4 (71.20 to 79.54)72.1 (62.61 to 81.57)
Week 3675.1 (70.94 to 79.31)72.1 (62.61 to 81.57)
Week 5275.4 (71.20 to 79.54)68.6 (58.80 to 78.41)
SecondaryPercentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response

ACR70 response is defined as a ≥ 70% improvement (reduction) compared with Baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

Time frame:
Weeks 4, 8, 12, 24, 36 and 52
Reported as:
Number · Percentage
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response
PercentageGDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
Week 419.8 (15.90 to 23.61)12.8 (5.73 to 19.85)
Week 821.7 (17.72 to 25.70)17.4 (9.42 to 25.46)
Week 1223.9 (19.77 to 28.03)19.8 (11.35 to 28.18)
Week 2430.2 (25.80 to 34.69)20.9 (12.33 to 29.53)
Week 3632.2 (27.67 to 36.72)25.6 (16.36 to 34.80)
Week 5236.3 (31.69 to 41.00)27.9 (18.43 to 37.39)
SecondaryDisease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 CRP)

The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36 and 52
Reported as:
Mean · Score on a scale
Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 CRP)
Score on a scaleGDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
Baseline5.49 ± 0.855.59 ± 0.90
Week 43.64 ± 1.114.09 ± 1.19
Week 83.48 ± 1.063.81 ± 1.15
Week 123.37 ± 1.093.73 ± 1.11
Week 243.16 ± 1.053.55 ± 1.18
Week 363.05 ± 1.053.36 ± 1.06
Week 522.90 ± 1.033.17 ± 1.28
SecondaryDisease Activity Score Based on 28-Joints Count and C-Reactive Protein (4 Variables) (DAS28-4 CRP)

The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36 and 52
Reported as:
Mean · Score on a scale
Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (4 Variables) (DAS28-4 CRP)
Score on a scaleGDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
Baseline5.83 ± 0.885.95 ± 0.94
Week 43.70 ± 1.194.22 ± 1.34
Week 83.53 ± 1.133.92 ± 1.25
Week 123.39 ± 1.143.81 ± 1.21
Week 243.18 ± 1.133.64 ± 1.27
Week 363.06 ± 1.143.44 ± 1.21
Week 522.87 ± 1.093.22 ± 1.40
SecondaryDisease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 ESR)

The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36 and 52
Reported as:
Mean · Score on a Scale
Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 ESR)
Score on a ScaleGDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
Baseline6.17 ± 0.796.38 ± 0.88
Week 44.25 ± 1.164.80 ± 1.26
Week 84.04 ± 1.144.51 ± 1.17
Week 123.89 ± 1.164.40 ± 1.11
Week 243.65 ± 1.084.15 ± 1.27
Week 363.46 ± 1.153.96 ± 1.15
Week 523.35 ± 1.143.74 ± 1.31
SecondaryDisease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 ESR)

The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36 and 52
Reported as:
Mean · Score on a Scale
Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 ESR)
Score on a ScaleGDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
Baseline6.48 ± 0.856.71 ± 0.96
Week 44.27 ± 1.254.89 ± 1.41
Week 84.04 ± 1.234.58 ± 1.29
Week 123.87 ± 1.234.44 ± 1.25
Week 243.62 ± 1.164.20 ± 1.37
Week 363.43 ± 1.243.99 ± 1.30
Week 523.27 ± 1.203.74 ± 1.42
SecondaryPercentage of Participants With Remission Based on Disease Activity Score Based on 28-Joints Count (DAS28)

The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control.

Time frame:
Weeks 4, 8, 12, 24, 36 and 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With Remission Based on Disease Activity Score Based on 28-Joints Count (DAS28)
Percentage of ParticipantsGDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
Week 48.87.0
Week 810.78.1
Week 1213.98.1
Week 2417.814.0
Week 3622.411.6
Week 5225.623.3
SecondaryPercentage of Participants With Low Disease Activity (LDA) Based on DAS28

The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. LDAS is defined as DAS28 ≤ 3.2

Time frame:
Weeks 4, 8, 12, 24, 36 and 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With Low Disease Activity (LDA) Based on DAS28
Percentage of ParticipantsGDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
Week 420.012.8
Week 821.217.4
Week 1226.612.8
Week 2433.727.9
Week 3638.329.1
Week 5242.229.1
SecondaryPercentage of Participants With ACR/EULAR Remission

Assessed according to the Boolean based definition (tender joint count =\<1, swollen joint count =\<1, C-reactive Protein (CRP) =\<1, and patient global assessment =\<1)

Time frame:
Weeks 4, 8, 12, 24, 36 and 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With ACR/EULAR Remission
Percentage of ParticipantsGDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
Week 45.05.8
Week 87.85.9
Week 127.47.2
Week 2413.06.0
Week 3615.611.4
Week 5217.810.7
SecondaryChange From Baseline in Simplified Disease Activity Index (SDAI)

Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity

Time frame:
Weeks 4, 8, 12, 24, 36 and 52
Reported as:
Mean · Score on a Scale
Change From Baseline in Simplified Disease Activity Index (SDAI)
Score on a ScaleGDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
Week 4-24.36 ± 13.58-21.00 ± 13.49
Week 8-26.17 ± 13.58-24.06 ± 13.57
Week 12-27.91 ± 12.89-25.21 ± 13.37
Week 24-29.61 ± 13.14-26.45 ± 14.17
Week 36-30.47 ± 13.72-28.22 ± 14.16
Week 52-31.69 ± 13.12-29.68 ± 13.77
SecondaryChange From Baseline in Clinical Disease Activity Index (CDAI)

CDAI was derived as the sum of the following: tender joint count (TJC), swollen joint count (SJC), participant global assessment (PGA) of disease activity, and physician assessment of disease activity. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA and physician assessment of disease activity were scored 0-100 millimeters (mm) and rounded to the nearest centimeter (cm) on a visual analog scale (VAS), where higher scores indicate greater perceived disease activity. The total CDAI score range was 0-76, where higher scores indicate increased disease activity. Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest. Negative values indicate improvement/reduction in RA disease activity.

Time frame:
Weeks 4, 8, 12, 24, 36 and 52
Reported as:
Mean · Score on a Scale
Change From Baseline in Clinical Disease Activity Index (CDAI)
Score on a ScaleGDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
Week 4-23.41 ± 13.11-19.81 ± 13.15
Week 8-25.14 ± 13.06-22.48 ± 12.59
Week 12-26.82 ± 12.31-23.82 ± 12.37
Week 24-28.52 ± 12.52-25.09 ± 13.18
Week 36-29.40 ± 12.99-26.66 ± 12.98
Week 52-30.61 ± 12.43-27.43 ± 13.43
SecondaryChange From Baseline in Tender/Painful Joint Count Based on 68 Joints

Tender Joint Count: a total of 68 joints will be assessed for tenderness. Each joint is assessed for the presence/absence of tenderness. 68 joints are assessed for tenderness and joints are classified as tender/not tender giving a total possible tender joint count score of 0 to 68. A negative change from Baseline indicated improvement.

Time frame:
Weeks 4, 8, 12, 24, 36 and 52
Reported as:
Mean · Score on a Scale
Change From Baseline in Tender/Painful Joint Count Based on 68 Joints
Score on a ScaleGDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
Week 4-15.02 ± 12.38-13.23 ± 12.27
Week 8-16.11 ± 12.45-15.19 ± 12.59
Week 12-16.55 ± 12.39-15.99 ± 12.03
Week 24-17.96 ± 12.24-16.65 ± 11.35
Week 36-18.48 ± 12.77-17.51 ± 11.60
Week 52-18.70 ± 12.99-17.73 ± 11.88
SecondaryChange From Baseline in Swollen Joint Count Based on 66 Joints

Swollen Joint Count: a total of 66 joints will be assessed for swelling. Each joint is assessed for the presence/absence of swelling. 66 joints were assessed for swelling and joints are classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66. A negative change from Baseline indicated improvement.

Time frame:
Weeks 4, 8, 12, 24, 36 and 52
Reported as:
Mean · Score on a Scale
Change From Baseline in Swollen Joint Count Based on 66 Joints
Score on a ScaleGDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
Week 4-10.20 ± 8.43-7.85 ± 6.71
Week 8-10.95 ± 8.48-9.12 ± 6.65
Week 12-11.40 ± 8.22-9.08 ± 6.84
Week 24-11.93 ± 8.33-9.86 ± 6.61
Week 36-12.15 ± 8.57-9.98 ± 6.96
Week 52-12.17 ± 8.55-9.59 ± 8.78
SecondaryChange From Baseline in Patient's Assessment of Arthritis Pain, Using Visual Analog Scale (VAS) Score

Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain

Time frame:
Weeks 4, 8, 12, 24, 36 and 52
Reported as:
Mean · Score on a Scale
Change From Baseline in Patient's Assessment of Arthritis Pain, Using Visual Analog Scale (VAS) Score
Score on a ScaleGDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
Week 4-30.62 ± 26.60-26.34 ± 25.98
Week 8-32.57 ± 26.77-27.21 ± 23.36
Week 12-35.68 ± 26.44-29.49 ± 26.70
Week 24-37.19 ± 26.85-30.30 ± 26.42
Week 36-39.50 ± 27.20-33.14 ± 27.22
Week 52-42.40 ± 26.22-38.21 ± 26.37
SecondaryChange From Baseline in Patient's Global Assessment of Arthritis, Using VAS Score

Participant-assessed arthritis pain was scored on a 100-mm VAS, where the distance from 0 mm represented the participant's self evaluation of arthritis pain (0 mm=none; 100 mm=very severe). Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest, where negative change indicated a decrease in participant-assessed arthritis pain.

Time frame:
Weeks 4, 8, 12, 24, 36 and 52
Reported as:
Mean · Score on a Scale
Change From Baseline in Patient's Global Assessment of Arthritis, Using VAS Score
Score on a ScaleGDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
Week 4-30.21 ± 27.47-26.03 ± 24.50
Week 8-32.67 ± 26.85-28.79 ± 23.07
Week 12-35.63 ± 26.19-31.16 ± 25.32
Week 24-36.94 ± 27.23-31.76 ± 25.09
Week 36-39.40 ± 26.77-33.73 ± 25.82
Week 52-42.91 ± 25.90-36.58 ± 24.74
SecondaryChange From Baseline in Physician's Global Assessment of Arthritis, Using VAS Score

Physician's assessment of participant's disease activity was scored on a 100-mm VAS, where the distance from 0 mm represented the physician's assessment of the participant's disease activity (0 mm=very good; 100 mm=very poor). Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest, where negative change from baseline indicated an improvement in physician-assessed disease activity.

Time frame:
Weeks 4, 8, 12, 24, 36 and 52
Reported as:
Mean · Score on a Scale
Change From Baseline in Physician's Global Assessment of Arthritis, Using VAS Score
Score on a ScaleGDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
Week 4-37.07 ± 20.75-30.65 ± 24.09
Week 8-39.29 ± 20.30-35.32 ± 22.36
Week 12-42.23 ± 20.20-37.37 ± 22.14
Week 24-44.40 ± 20.94-41.11 ± 23.86
Week 36-45.52 ± 20.76-43.13 ± 24.14
Week 52-48.57 ± 19.99-44.81 ± 23.85
SecondaryChange From Baseline in C-Reactive Protein (CRP) Levels

C-reactive protein is a biological marker of inflammation and is measured in milligrams per decilitre (mg/dL)

Time frame:
Weeks 4, 8, 12, 24, 36 and 52
Reported as:
Mean · (mg/dL)
Change From Baseline in C-Reactive Protein (CRP) Levels
(mg/dL)GDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
Week 4-0.95 ± 2.18-1.09 ± 3.10
Week 8-1.02 ± 2.41-1.58 ± 2.60
Week 12-1.03 ± 2.21-1.40 ± 3.38
Week 24-1.03 ± 2.48-1.46 ± 2.99
Week 36-1.11 ± 2.44-1.56 ± 3.04
Week 52-1.12 ± 2.55-1.81 ± 2.75
SecondaryChange From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score

The Stanford Health Assessment Questionnaire disability index is a patient-reported outcome used to assess difficulty in performing activities of daily living. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. To respond to each question, a four-level response with higher scores showing larger functional limitations, was chosen. Scoring is as follows with respect to performance of participant's everyday activities: 0 (equals)=without difficulties; 1= with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. The composite HAQ-DI score is the mean of the eight domain scores and the score ranges from 0 (no functional impairment) to 3 (maximum functional impairment). A negative change from baseline indicates improvement.

Time frame:
Weeks 4, 8, 12, 24, 36 and 52
Reported as:
Mean · Score on a Scale
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score
Score on a ScaleGDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
Week 4-0.70 ± 0.64-0.55 ± 0.56
Week 8-0.77 ± 0.65-0.59 ± 0.62
Week 12-0.80 ± 0.67-0.60 ± 0.59
Week 24-0.83 ± 0.66-0.63 ± 0.58
Week 36-0.89 ± 0.63-0.62 ± 0.66
Week 52-0.98 ± 0.64-0.69 ± 0.62
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) Version 2.0 (V2) Scores for Physical and Mental Components

The 36-Item Short Form Health Survey (SF-36v2) is a questionnaire used to assess functional health and well-being and consists of eight domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. The SF-36v2 is summarized into Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. The PCS and MCS scores range from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.

Time frame:
Weeks 12, 24 and 52
Reported as:
Mean · Number on a Scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Version 2.0 (V2) Scores for Physical and Mental Components
Number on a ScaleGDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
Week 12 (Physical Component Score change)11.35 ± 9.138.22 ± 8.73
Week 12 (Mental Component Score change)6.52 ± 12.984.74 ± 11.53
Week 24 (Physical Component Score change)12.31 ± 9.128.28 ± 8.53
Week 24 (Mental Component Score change)6.63 ± 13.236.08 ± 11.76
Week 52 (Physical Component Score change)13.89 ± 9.3210.42 ± 8.94
Week 52 (Mental Component Score change)7.00 ± 13.816.77 ± 11.60
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score

The FACIT-Fatigue Scale consists of 13 items designed to measure the degree of fatigue experienced by the patient in the previous 7 days. For each question, there are five possible responses: 0 (not at all), 1 (a little bit), 2 (somewhat), 3 (quite a bit), 4 (very much). A total fatigue score is calculated by summing all items, and possible total scores range from 0 (maximum fatigue) to 52 (no fatigue). A positive change from baseline indicates an improvement in the patient's fatigue (less fatigue).

Time frame:
Weeks 12, 24 and 52
Reported as:
Mean · Score on a Scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score
Score on a ScaleGDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
Week 1211.44 ± 10.369.28 ± 8.51
Week 2411.74 ± 10.7510.41 ± 8.51
Week 5212.87 ± 10.5810.87 ± 9.25
SecondaryArea Under the Concentration Time Curve (AUC) of GDC-0853 at Steady State (AUC,ss)

Population PK model estimated AUC of GDC-0853 at steady-state. AUC was measured in Nanograms (ng) per millilitre(mL)\*hour (hr).

Time frame:
Pre-dose (0 hour) on Weeks 0 (Day 1), 4, 12, 24, 36, and 52/early termination
Reported as:
Mean · Ng/mL*(hr)
Area Under the Concentration Time Curve (AUC) of GDC-0853 at Steady State (AUC,ss)
Ng/mL*(hr)GDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
Area Under the Concentration Time Curve (AUC) of GDC-0853 at Steady State (AUC,ss)13400 ± 693015600 ± 7850
SecondaryMinimum Plasma Concentration of GDC-0853 at Steady State (Ctrough,ss)

Population PK model estimated minimal plasma concentration (Ctrough) of GDC-0853 at steady-state (ss).

Time frame:
Pre-dose (0 hour) on Weeks 0 (Day 1), 4, 12, 24, 36, and 52/early termination
Reported as:
Mean · ng/mL
Minimum Plasma Concentration of GDC-0853 at Steady State (Ctrough,ss)
ng/mLGDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
Minimum Plasma Concentration of GDC-0853 at Steady State (Ctrough,ss)387 ± 244467 ± 285
SecondaryPlasma Decay Half-Life of GDC-0853 at Steady State (t1/2,ss)

Population PK model estimated plasma decay half life of GDC-0853 at steady-state.

Time frame:
Pre-dose (0 hour) on Weeks 0 (Day 1), 4, 12, 24, 36, and 52/early termination
Reported as:
Mean · hr
Plasma Decay Half-Life of GDC-0853 at Steady State (t1/2,ss)
hrGDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
Plasma Decay Half-Life of GDC-0853 at Steady State (t1/2,ss)7.94 ± 3.169.01 ± 4.9
SecondaryApparent Oral Clearance of GDC-0853 at Steady State (CL/F,ss)

Population PK model estimated apparent oral clearance of GDC-0853 at steady-state.

Time frame:
Pre-dose (0 hour) on Weeks 0 (Day 1), 4, 12, 24, 36, and 52/early termination
Reported as:
Mean · L/hr
Apparent Oral Clearance of GDC-0853 at Steady State (CL/F,ss)
L/hrGDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
Apparent Oral Clearance of GDC-0853 at Steady State (CL/F,ss)39.5 ± 12.635.3 ± 10.3

Adverse events

Collected over Day 1 up until 8 weeks after the last dose of study drug (up to 1 year, 2 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GDC-0853 (200mg BID) Cohort 13/410 (0.7%)26/410 (6.3%)22/410 (5.4%)
GDC-0853 (200mg BID) Cohort 20/86 (0%)4/86 (4.7%)4/86 (4.7%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventGDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
ATRIAL FIBRILLATIONCardiac disorders0/4101/86
PNEUMONIAInfections and infestations0/4101/86
HIP FRACTUREInjury, poisoning and procedural complications1/4101/86
BASAL CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4101/86
ACUTE KIDNEY INJURYRenal and urinary disorders2/4100/86
VAGINAL HAEMORRHAGEReproductive system and breast disorders2/4100/86
IRON DEFICIENCY ANAEMIABlood and lymphatic system disorders1/4100/86
CARDIO-RESPIRATORY ARRESTCardiac disorders1/4100/86
DIARRHOEAGastrointestinal disorders1/4100/86
ENTEROCOLITISGastrointestinal disorders1/4100/86
Most frequent other events
Most frequent other events
EventGDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2
URINARY TRACT INFECTIONInfections and infestations22/4104/86

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2Total
Mean49.9 ± 11.753.5 ± 12.550.5 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)GDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2Total
Female33464398
Male762298
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2Total
Hispanic or Latino13630166
Not Hispanic or Latino26756323
Not Stated202
Unknown505
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GDC-0853 (200mg BID) Cohort 1GDC-0853 (200mg BID) Cohort 2Total
American Indian or Alaska native271138
Asian101
Black or African American729
Multiple729
Unknown303
White36571436
08

Study locations

104 sites
  • Arizona Arthritis & Rheumatology Associates, P.C.
    Glendale, Arizona 85306, United States
  • Medvin Clinical Research
    Covina, California 91723, United States
  • TriWest Research Associates, LLC
    El Cajon, California 92020, United States
  • Saint Jude Heritage Medical Grp
    Fullerton, California 92835, United States
  • RASF-Clinical Research Center
    Boca Raton, Florida 33486, United States
  • Clinical Research of West Florida
    Clearwater, Florida 33765, United States
  • Medication Management
    Greensboro, North Carolina 27408, United States
  • Oregon Health & Science Uni
    Portland, Oregon 97239, United States
  • Metroplex Clinical Research Centre
    Dallas, Texas 75231, United States
  • Baylor Research Inst.
    Dallas, Texas 75246, United States
  • Accurate Clinical Research
    Houston, Texas 77089, United States
  • Instituto de Investigaciones Clinicas-Mar del Plata
    Buenos Aires, B7600FZN, Argentina
  • APRILLUS
    Buenos Aires, C1194AAO, Argentina
  • Instituto centenario
    Buenos Aires, C1204AAD, Argentina
  • Centro de Investigacion en Enfermedades Reumaticas CIER
    Ciudad Autonoma Buenos Aires, C1055AAF, Argentina
  • Expertia S.A- Mautalen Salud e Investigación
    Ciudad Autonoma Buenos Aires, C1128AAE, Argentina
  • CCBR - Buenos Aires - AR; AxisMed SRL
    Ciudad Autonoma Buenos Aires, C1430CKE, Argentina
  • ILAIM-CEOM Inst. Latinoamericano de Inv. Medicas
    Cordoba, X5000BNB, Argentina
  • Centro de Investigaciones Medicas Mar Del Plata
    Mar del Plata, B7600DHK, Argentina
  • Instituto de Investigaciones Clinicas
    Rosario, S2000CVD, Argentina
  • CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica
    San Juan, 5400, Argentina
  • Centro Medico Privado de Reumatologia; Reumathology
    San Miguel, T4000AXL, Argentina
  • CIP - Centro Internacional de Pesquisa X; Pesquisa Clinica
    Goiânia, GO 74110-120, Brazil
  • CMiP - Centro Mineiro de Pesquisa*X*
    Juiz de Fora, MG 36010-570, Brazil
  • Centro de Estudos em Terapias Inovadoras - CETI
    Curtiba, PR 80030-110, Brazil
  • CCBR Brasil Centro de Pesquisas e Análises Clínicas Ltda.
    Rio de Janeiro, RJ 21941-913, Brazil
  • LMK Serviços Médicos S/S
    Porto Alegre, RS 90480-000, Brazil
  • CAEP - Centro Avancado de Estudos e Pesquisas Ltda.
    Campinas, SP 13087-567, Brazil
  • IMA Brasil - Instituto de Medicina Avancada
    Sao Paulo, SP 05437-000, Brazil
  • MHAT "Eurohospital" - Plovdiv, OOD; Internal Department
    Plovdiv, 4002, Bulgaria
  • UMHAT "Kaspela", EOOD
    Plovdiv, 4002, Bulgaria
  • Medizinski Zentrar-1-Sevlievo EOOD
    Sevlievo, 5400, Bulgaria
  • MHAT "Hadzhi Dimitar", OOD
    Sliven, 8800, Bulgaria
  • Medical Center Excelsior OOD
    Sofia, 1000, Bulgaria
  • NMTH "Tsar Boris III"
    Sofia, 1233, Bulgaria
  • DCC "Alexandrovska", EOOD; Clinic of Neurology
    Sofia, 1431, Bulgaria
  • MC "Synexus - Sofia", EOOD
    Sofia, 1784, Bulgaria
  • UMHAT "SofiaMed", OOD; Department of Neurology
    Sofia, 1797, Bulgaria
  • Centro de Investigacion Medico Asistencial S.A.S
    Barranquilla, 80020, Colombia
  • Centro de Investigacion en Reumatologia y Especialdades Medicas SAS. CIREEM
    Bogota, 110221, Colombia
  • Riesgo de Fractura S.A.
    Bogota, 110221, Colombia
  • Consultorio Medico en Fundacion el Hospitalito de morelos A.C.
    Cuernavaca, Morelos 62170, Mexico
  • Centro de Investigacion en Reumatologia
    Merida, Yucatan 97070, Mexico
  • Consultorio Particular del Dr. Miguel Cortes Hernandez
    Cuernavaca, 62290, Mexico
  • Centro de Investigacion de Tratam Innovadores de Sin SC
    Culiacan, 80230, Mexico
  • Centro de Investigacion en Enfermedades Reumaticas y Osteoporosis
    Mexicali, 21100, Mexico
  • Centro de Investigacion Clínica GRAMEL S.C
    Mexico, 03720, Mexico
  • Policlinica Medica de Queretaro S.C.
    Queretaro, 76000, Mexico
  • Clinical Research Institute
    Tlalnepantla, 54055, Mexico
  • Unidad de Enfermedades Reumaticas y Cronicodegenerativas
    Torreon, 27000, Mexico
  • NZOZ ZDROWIE Osteo-Medic
    Bialystok, 15-351, Poland
  • Szpital Uniwersytecki; nr 2 im. Dr J. Biziela
    Bydgoszcz, 85-168, Poland
  • Centrum Medyczne Pratia Katowice I
    Katowice, 40-081, Poland
  • CCBR - Lodz - PL
    Lodz, 90-368, Poland
  • ETYKA Osrodek Badan Kliniczynch
    Olsztyn, 10-117, Poland
  • Ai Centrum Medyczne Sp. Z O.O Sp.K.
    Poznan, 61-113, Poland
  • Medycyna Kliniczna
    Warszawa, 00-660, Poland
  • Centrum Medyczne AMED
    Warszawa, 03-291, Poland
  • KO-MED Centra Kliniczne Zamosc
    Zamosc, 22400, Poland
  • SBIH of Yaroslavl region " Regional Clinical Hospital "; Therapy
    Yaroslavl, Jaroslavl 150062, Russian Federation
  • Federal State Budgetary Scientific Institution Research Institute of Rheumatology V.A. Nasonova
    Moscow, Moskovskaja Oblast 115522, Russian Federation
  • SBIH of Moscow "City Clinical Hospital # 1 n. a. N. I. Pirogov"
    Moscow, Moskovskaja Oblast 119049, Russian Federation
  • SPb SBIH "Clinical Rheumatological Hospital # 25"
    Saint-Petersburg, Sankt Petersburg 190068, Russian Federation
  • Sanavita LLC
    Sankt-peterburg, Sankt Petersburg 195257, Russian Federation
  • LLC Medical Sanitary Unit
    Sankt-peterburg, Sankt Petersburg 196066, Russian Federation
  • Center of Family Medicine LC
    Yekaterinburg, Sankt Petersburg 620043, Russian Federation
  • SBHI of Yaroslavl Region Clinical Hospital #3
    Yaroslavl, Volgograd 150051, Russian Federation
  • SMMIH "Chelyabinsk Regional Clinical Hospital"
    Chelyabinsk, Voronez 454076, Russian Federation
  • SAHI of Kem. "Regional Clinical Hospital for War Veterans"
    Kemerovo, 650000, Russian Federation
  • OOO Family Polyclinic
    Korolev, Moscow Region, 141060, Russian Federation
  • Practical Medicine
    Moscow, 115404, Russian Federation
  • Limited Liability Company "Centre of Medical Common Practice"
    Novosibirsk, 630091, Russian Federation
  • Ultramed
    Omsk, 644024, Russian Federation
  • SEIHPE Saratov State Medical University n.a. V.I. Razumovskiy
    Saratov, 410012, Russian Federation
  • NIH "Departmental Hospital on Station Smolensk of OJSC "Russian Railways"
    Smolensk, 214025, Russian Federation
  • Siberian State Medical University
    Tomsk, 634050, Russian Federation
  • SHI Ulyanovsk Reg Clinical Hospital
    Ulyanovsk, 432063, Russian Federation
  • Territorial Clinical Hospital #2
    Vladivostok, 690035, Russian Federation
  • Institute of Rheumatology
    Belgrade, 11000, Serbia
  • Clinical Center Kragujevac
    Kragujevac, 34000, Serbia
  • Institute of Treatment and Rehabilitation "Niska Banja"
    Niska Banja, 18205, Serbia
  • Special hospital for rheumatic diseases Novi Sad
    Novi Sad, 21000, Serbia
  • General Hospital "Dr Laza K. Lazarevic" Sabac
    Sabac, 15000, Serbia
  • MI of Healthcare Kyiv RCH P.L. Shupyk NMA of PGE
    Kyiv, Chernihiv Governorate 01601, Ukraine
  • CI of Healthcare Kharkiv CCH #8 Dept of Therapy Kharkiv MA of PGE of MOHU
    Kharkiv, Kharkiv Governorate 61176, Ukraine
  • CI of TRC
    Ternopil, Kherson Governorate 46002, Ukraine
  • Regional CH Dep of Rheumatology SHEI Ivano-Frankivsk NMU
    Ivano-Frankivsk, KIEV Governorate 76008, Ukraine
  • SI NSС M.D. Strazhesko Institute of Cardiology of NAMSU
    Kyiv, KIEV Governorate 03680, Ukraine
  • Medical Center of Revmotsentr LLC
    Kyiv, KIEV Governorate 04070, Ukraine
  • Medical Center of Limited Liability Company Medical Clinic Blagomed
    Kyiv, KIEV Governorate 1023, Ukraine
  • Med Center of International Institute of Clinical Trials LLC; Medical Center "OK!Clinic+"
    Kyiv, KIEV Governorate 2091, Ukraine
  • Lviv Regional Clinical Hospital Dept of Rehmuaatology D. Halytskyi Lviv NMU
    Lviv, KIEV Governorate 79010, Ukraine
  • CH of State Border Service of Ukraine (Military Base 2522); Dept of Therapy, D.Halytskyi Lviv NMU
    Lviv, KIEV Governorate 79014, Ukraine
  • A.Novak Transcarpathian Regional Clinical Hospital
    Uzhgorod, KIEV Governorate 88018, Ukraine
  • National Pirogov Memorial Medical University
    Vinnytsia, Podolia Governorate 21018, Ukraine
  • Railway Transp DCH of HealthCenter Branch of PJSC Ukr Railway Dept of Rheumatology
    Dnipro, Tavria Okruha 49008, Ukraine
  • City Clinical Hospital #9 Dept of Therapy SI Zaporizhzhia MA of PGE of MoHU
    Zaporizhzhia, Tavria Okruha 69065, Ukraine
  • CI City Hospital #1
    Zaporizhzhia, Tavria Okruha 69104, Ukraine
  • CI Lutsk CCH Volyn Regional Center of Cardiovascular Pathology and Thrombolysis
    Lutsk, Volhynian Governorate 43024, Ukraine
  • GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine
    Kharkiv, 61039, Ukraine

Showing the first 100 of 104 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Jul 2019, 31 months.

Results were first posted in Aug 2020, 1 year after primary completion.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 31 months is above that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2016
First posted
Dec 6, 2016
StartActual
Nov 30, 2016
Primary completionActual
Jul 17, 2019
CompletionActual
Jul 17, 2019
Results first posted
Aug 3, 2020
Last update
Aug 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02983227
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Dec 6, 2016
Start date
Nov 30, 2016
Primary completion
Jul 17, 2019
Completion
Jul 17, 2019
Results posted
Aug 3, 2020
Last update
Aug 3, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fenebrutinib

Start the discussion